Senior Management Led | Transactions

Predictive Therapeutics Has Issued 5,000,000 Shares of Series A Preferred Stock

Has Issued 5,000,000 Shares of Series A Preferred Stock

About Predictive Therapeutics

Predictive Therapeutics is a clinical stage oncology company, with a focus on immunotherapy. We seek to acquire undervalued late stage assets for clinical development. Our goal is to unlock the potential of these promising cancer therapies in order to bring effective and safe drugs to patients.

More Transactions

Completed Series C Financing

The undersigned served as Strategic and Financial Advisor to NanoHive.

has sold its assets to

The undersigned acted as exclusive strategic & financial advisor to Direct Diagnostics

has acquired the assets of

The undersigned acted as exclusive strategic & financial advisor to Athersys, Inc.
Maxim Biomedical, Inc.

has received a minority investment from

PVFO
The undersigned acted as exclusive strategic and financial advisor to Maxim Biomedical, Inc.

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    20 Custom House St, Suite 1200, Boston, MA 02110
    (617) 431-2278

© Outcome Capital 2024. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.

Business Continuity Plan | Privacy Policy | Regulation Best Interest

Built by Metropolis